Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 72, Issue 6, Pages 949-954Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2012-201506
Keywords
-
Categories
Funding
- NIH [AR 057578, AR 055989]
- Amgen Canada Inc.
- Pfizer Canada Inc.
- Hoffmann-La Roche Ltd.
- United Chemicals of Belgium (UCB) Canada Inc.
- Bristol-Myers Squibb Canada Co.
- Abbott Laboratories Ltd.
- Janssen Biotech Inc. (Johnson Johnson Inc.)
- Forest
- Merck Canada
- Novartis
- Amgen
- Warner-Chilcott
- Janssen
- Abbott
- Institut de rheumatologie de Montreal
- UCB
- AstraZeneca
- BMS
- Roche
- Johnson and Johnson
- Pfizer
- Actelion
- Glaxo Smith Kline
- Centocor
- Genzyme
- Merck
- Lilly
Ask authors/readers for more resources
Objectives Secondary fibromyalgia (FM) is common among patients with inflammatory arthritis, but little is known about its incidence and the factors leading to its development. The authors examined the incidence of secondary FM in an early inflammatory arthritis cohort, and assessed the association between pain, inflammation, psychosocial variables and the clinical diagnosis of FM. Methods Data from 1487 patients in the Canadian Early Arthritis Cohort, a prospective, observational Canadian cohort of early inflammatory arthritis patients were analysed. Diagnoses of FM were determined by rheumatologists. Incidence rates were calculated, and Cox regression models were used to determine HRs for FM risk. Results The cumulative incidence rate was 6.77 (95% CI 5.19 to 8.64) per 100 person-years during the first 12 months after inflammatory arthritis diagnosis, and decreased to 3.58 (95% CI 1.86 to 6.17) per 100 person-years 12-24 months after arthritis diagnosis. Pain severity (HR 2.01, 95% CI 1.17 to 3.46) and poor mental health (HR 1.99, 95% CI 1.09 to 3.62) predicted FM risk. Citrullinated peptide positivity (HR 0.48, 95% CI 0.26 to 0.88) was associated with decreased FM risk. Serum inflammatory markers and swollen joint count were not significantly associated with FM risk. Conclusions The incidence of FM was from 3.58 to 6.77 cases per 100 person-years, and was highest during the first 12 months after diagnosis of inflammatory arthritis. Although inflammation was not associated with the clinical diagnosis of FM, pain severity and poor mental health were associated with the clinical diagnosis of FM. Seropositivity was inversely associated with the clinical diagnosis of FM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available